Benitec Biopharma lost $12.9 million last quarter and shared updates on its BB-301 gene therapy, showing a 100% response rate.

Nov 13, 2026, 9:18 AM ETResultsRead the original at quantisnow.com

Good for BNTC

BB-301 showed a 100% responder rate in Cohorts 1 and 2, with no serious side effects reported. The loss grew to $12.9 million from $9.0 million, but the treatment results and $176.5 million cash balance make the update favorable for Benitec.

BNTC · Benitec Biopharma

AI read · Good for BNTC

The AI's read

The treatment findings are the clearest positive sign because every patient in the 2 reported groups responded, and no serious side effects have been seen so far. The larger loss is a concern, but the cash balance gives Benitec funds to keep working on the treatment.

Get alerts for BNTC

Follow Benitec Biopharma (BNTC) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BNTC

Free on the App Store and Google Play, or on the web.